Biogen Idec, Roche To Stop Ocrelizumab’s Rheumatoid Arthritis Trial – Update – RTT News

By Dr. Matthew Watson


Earthtimes (press release)
Biogen Idec, Roche To Stop Ocrelizumab's Rheumatoid Arthritis Trial - Update
RTT News
(RTTNews) - Biotechnology company Biogen Idec Inc. (BIIB: News ) and its Swiss peer Roche Holding AG (RHHBY.PK: News ) Wednesday stated that they decided to ...
Roche, Biogen end arthritis drug developmentReuters

all 26 news articles »



categoriaUncategorized commentoComments Off on Biogen Idec, Roche To Stop Ocrelizumab’s Rheumatoid Arthritis Trial – Update – RTT News | dataMay 19th, 2010

About...

This author published 5872 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024